Agomelatine Reverses Scopolamine-Induced Learning and Memory Impairment in Adult Rats
Open Access
- 1 December 2021
- journal article
- research article
- Published by Online Turk Saglik Bilimleri Dergisi in Online Türk Sağlık Bilimleri Dergisi
- Vol. 6 (4) , 535-541
Abstract
Objective: The antidepressant agomelatine agent is a melatonin receptor (MT1 and MT2) agonist and a serotonin receptor (5-HT2C) antagonist. Increasing evidence shows that agomelatine has neuroprotective and neuromodulatory effects. In this study, the potential effects of agomelatine in rats with scopolamine-induced cognitive impairment were investigated.Materials and Methods: Adult male rats were administered scopolamine (1 mg/kg) and agomelatine (40 mg/kg) for 21 days. After drug administration, rats were subjected to new object recognition (NOR) and Morris water maze (MWM) tests in order to evaluate cognitive behaviors. In addition, brain-derived neurotrophic factor (BDNF) and acetylcholine (ACh) levels in the hippocampus and prefrontal cortex were evaluated.Results: Scopolamine significantly decreased both spatial memory and discrimination index (p0.05). In addition, agomelatine significantly increased BDNF levels in both hippocampus and prefrontal cortex compared to the scopolamine group (p<0.05, p0.05).Conclusion: Taken together, these results demonstrated that agomelatine plays a important role in alleviating scopolamine-induced memory impairment. Therefore, we suggest that agomelatine may be a potential agent in the prevention of cognitive impairment.Keywords
This publication has 29 references indexed in Scilit:
- Role of central angiotensin receptors in scopolamine-induced impairment in memory, cerebral blood flow, and cholinergic functionPsychopharmacology, 2012
- Rehmannia glutinosa Ameliorates Scopolamine-Induced Learning and Memory Impairment in RatsJournal of Microbiology and Biotechnology, 2011
- Revisiting the cholinergic hypothesis in the development of Alzheimer's diseaseNeuroscience & Biobehavioral Reviews, 2011
- Beneficial behavioural and neurogenic effects of agomelatine in a model of depression/anxietyInternational Journal of Neuropsychopharmacology, 2011
- The validity of scopolamine as a pharmacological model for cognitive impairment: A review of animal behavioral studiesNeuroscience & Biobehavioral Reviews, 2010
- Synergistic mechanisms in the modulation of the neurotrophin BDNF in the rat prefrontal cortex following acute agomelatine administrationThe World Journal of Biological Psychiatry, 2010
- Differential Effects of Scopolamine on Memory Processes in the Object Recognition Test and the Morris Water Maze Test in MiceBiomolecules & Therapeutics, 2008
- The cholinesterase inhibitor, phenserine, improves Morris water maze performance of scopolamine-treated ratsLife Sciences, 2005
- Effect of Agomelatine in the Chronic Mild Stress Model of Depression in the RatNeuropsychopharmacology, 2002
- A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral dataBehavioural Brain Research, 1988